In the randomized Phase 2 trial, investigators studied the efficacy of combining the monoclonal antibody sintilimab with the histone deacetylase inhibitor chidamide (HDACi) with or without the monoclonal antibody bevacizumab in patients with chemotherapy-refractory unresectable colorectal cancer with stable/effective microsatellite mismatch repair (MSS/pMMR). A total of 48 patients were randomly assigned to either the doublet arm (sintilimab and chidamide, n = 23) or the triplet arm (sintilimab, chidamide and bevacizumab, n = 25). The primary endpoint, progression-free survival at 18 weeks, was achieved in 43.8% of patients. The triplet group showed significantly improved results compared with the doublet group.
Last press reviews
COVID-19 and coagulation parameters: a link to mortality?
The COVID-19 pandemic, caused by SARS-CoV-2, has led to millions of deaths...
Resistance training and Multiple Sclerosis: a solution to improve function and quality of life?
Multiple sclerosis (MS) is a chronic autoimmune disease of the central ner...
Endometriosis: the Impact of hormones, sexual practice, and surgical treatments
Endometriosis is a chronic inflammatory disease modulated by estrogen leve...